BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23686804)

  • 1. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
    Han X; Ji Y; Zhao J; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.
    Han X; Zhao J; Ji Y; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2881-9. PubMed ID: 23686805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
    Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
    Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors.
    Estrella JS; Broaddus RR; Mathews A; Milton DR; Yao JC; Wang H; Rashid A
    Arch Pathol Lab Med; 2014 Aug; 138(8):1027-36. PubMed ID: 25076292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Foo WC; Rashid A; Wang H; Katz MH; Lee JE; Pisters PW; Wolff RA; Abbruzzese JL; Fleming JB; Wang H
    Hum Pathol; 2013 Jun; 44(6):1024-30. PubMed ID: 23260327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
    Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
    Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
    Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
    Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.
    Lee D; Do IG; Choi K; Sung CO; Jang KT; Choi D; Heo JS; Choi SH; Kim J; Park JY; Cha HJ; Joh JW; Choi KY; Kim DS
    Mod Pathol; 2012 Jan; 25(1):131-9. PubMed ID: 21874010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
    Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
    Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases.
    Zhou CF; Ji J; Yuan F; Shi M; Zhang J; Liu BY; Zhu ZG
    Hepatogastroenterology; 2011; 58(112):2140-3. PubMed ID: 22024086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
    Shin E; Choi CM; Kim HR; Jang SJ; Park YS
    Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
    Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
    Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
    Yang J; Liao D; Wang Z; Liu F; Wu G
    J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
    Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
    Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.